LYRA - Lyra Therapeutics, Inc.
IEX Last Trade
0.1924
0.003 1.559%
Share volume: 21,674
Last Updated: Fri 27 Dec 2024 08:22:21 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.19
0.00
1.58%
Fundamental analysis
19%
Profitability
18%
Dept financing
10%
Liquidity
75%
Performance
10%
Performance
5 Days
3.26%
1 Month
-4.95%
3 Months
-32.03%
6 Months
-30.54%
1 Year
-96.46%
2 Year
-94.48%
Key data
Stock price
$0.19
DAY RANGE
$0.18 - $0.20
52 WEEK RANGE
$0.18 - $6.79
52 WEEK CHANGE
-$96.55
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Maria Palasis
Region: US
Website: lyratherapeutics.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lyratherapeutics.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Lyra Therapeutics, Inc. focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial.
Recent news